Maternal infection
The data available on maternal serious infection requiring
hospitalisation included two studies both of which focused on anti-TNF-α
use in pregnancy. There was a total of 1685 pregnant women in this
cohort.18,19 There were 916 women who were treated
with biologics during their pregnancy (Table 2) and 453 disease matched
control. The studies included in this analysis were
Chaparro19 who focused on anti-TNF-α use in IBD and
pregnancy and Clowse18 on certolizumab pegol use in
CID in pregnancy.
Overall the pooled analysis showed that the treated group had a
proportion of serious infection of 4% (95% CI 0.03 to 0.05), while the
disease matched group had a proportion of serious infections of 1%
(0.00 to 0.02) (Figure S9). There were only 2 studies included in this
analysis with a statistical difference in proportions between disease
matched compared with disease treated women (p <0.001.; Table
S2).